Related Experiment Videos
Hematologic depression following therapy with strontium-89 chloride
Clinical Nuclear Medicine
|December 1, 1986
Summary
Strontium-89 (Sr-89) chloride can cause bone marrow depression in some patients with painful skeletal metastases. Close hematological monitoring is crucial, especially for those with significant bone marrow tumor infiltration.
Area of Science:
- Oncology
- Radiopharmaceuticals
- Hematology
Background:
- Strontium-89 (Sr-89) chloride is used to treat painful skeletal metastases.
- Initial trials reported minimal hematological side effects.
Observation:
- A patient developed significant bone marrow depression after Sr-89 administration.
- This event was temporally linked to the radiostrontium treatment.
Findings:
- Bone marrow tumor replacement may increase susceptibility to Sr-89-induced marrow depression.
- This case highlights a potential risk not seen in initial studies.
Implications:
- Close hematological monitoring is essential for all patients receiving Sr-89.
- Caution is advised when treating patients with extensive bone marrow involvement.